机构：[1]Department of Pulmonary & Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.四川大学华西医院[2]State Key Laboratory of Respiratory Health & Multimorbidity, West China Hospital, Chengdu, 610041, Sichuan, China.四川大学华西医院[3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.四川大学华西医院[4]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, 610041, Sichuan, China.四川大学华西医院
Inhibitors of COX-2 constitute a class of anti-inflammatory analgesics, showing potential against certain types of cancer. However, such inhibitors are associated with cardiovascular toxicity. Moreover, although single-target molecules possess specificity for particular targets, they often lead to poor safety, low efficacy and drug resistance due to compensatory mechanisms. A new generation of dual-target drugs that simultaneously inhibit COX-2 and another target is showing strong potential to treat cancer or reduce adverse cardiac effects. The present perspective focuses on the structure and functions of COX-2, and its role as a therapeutic target. It also explores the current state and future possibilities for dual-target strategies from a medicinal chemistry perspective.
基金：
This review was supported by National Natural Science Foundation of China (no. 92159302 to W Li), the Science and Technology
Project of Sichuan (no. 2022ZDZX0018 to W Li), 1.3.5 project for disciplines of excellence,West China Hospital, Sichuan University
(no. ZYGD22009 to W Li).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|4 区医学
小类|4 区药物化学
最新[2023]版：
大类|4 区医学
小类|4 区药物化学
第一作者：
第一作者机构：[1]Department of Pulmonary & Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.[2]State Key Laboratory of Respiratory Health & Multimorbidity, West China Hospital, Chengdu, 610041, Sichuan, China.
通讯作者：
通讯机构：[1]Department of Pulmonary & Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.[2]State Key Laboratory of Respiratory Health & Multimorbidity, West China Hospital, Chengdu, 610041, Sichuan, China.[3]Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.[4]The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, 610041, Sichuan, China.
推荐引用方式(GB/T 7714)：
Zhang Fengmei,Zhu Guonian,Li Yangqian,et al.Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives[J].Future Medicinal Chemistry.2023,15(23):2209-2233.doi:10.4155/fmc-2023-0192.
APA：
Zhang Fengmei,Zhu Guonian,Li Yangqian,Qi Yawen,Wang Zhoufeng&Li Weimin.(2023).Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives.Future Medicinal Chemistry,15,(23)
MLA：
Zhang Fengmei,et al."Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives".Future Medicinal Chemistry 15..23(2023):2209-2233
